Join us at the 2021 World Microbe Forum!
June 20 – 24, 2021
We’re excited to announce that we will be participating in the 2021 World Microbe Forum (WMF), taking place virtually June 20 – 24. Be sure to check out our Industry and Science Symposia, Office Hours and Abstracts below.
Industry and Science Symposia
Utilization of the GenMark Dx ePlex Rapid Diagnostic To Study the Epidemiology of Antimicrobial Resistant Gram-Negative Bloodstream Infections
Available On-Demand Beginning:
June 20, 2021, 12:30pm – 1:00pm PDT | 3:30pm – 4:00pm EDT
Description
Gram-negative bacteremia ranks as one of the most serious clinical problems worldwide. Choosing the right antibiotic therapy for these infections can be critical, especially when these pathogens may contain genes that render the pathogen resistant to different classes of antibiotics. In this informative session, Dr. Trish Simner will discuss how the team at Johns Hopkins University School of Medicine conceptualized a study to take an in-depth look at the prevalence of the Extended-Spectrum Beta-Lactamase gene blaCTX-M in gram-negative bloodstream infection isolates in 66 hospitals located in different geographies across the United States. She will also discuss how the ePlex Blood Culture Identification Gram-Negative Panel has become an important tool in the day-to-day clinical operations at Johns Hopkins. Learn more.
Featured Speaker
Trish Simner, PhD, D(ABMM)
Associate Professor of Pathology
Director of Medical Bacteriology & Infectious Disease Sequencing Laboratories
Johns Hopkins University School of Medicine
Abstracts
Blood Culture Identification Panels
Rapid Identification and Antimicrobial Susceptibility Testing of Carbapenem-resistant Organisms with GenMark Dx ePlex® Blood Culture Gram-negative Identification Panels and the Specific Reveal™ System
Session CPHMP103 – CPHM02 Antimicrobial Susceptibility Testing – Rapid Testing
June 20, 2021, 5:30am – 2:00pm PDT | 8:30am – 5:00pm EDT
Authors
K. Khomtchouk, N. Whitfield, T. Smith, L. Rajeev, P. Singh, P. Rhodes
Specific Diagnostics, Inc (Mountain View, CA) and GenMark Diagnostics (Carlsbad, CA)
The GenMark Dx ePlex® Blood Culture Identification Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad) detects 21 GN bacteria and 6 antimicrobial resistance genes (ARG) (CTX-M, KPC, NDM, IMP, VIM and OXA) in positive blood cultures (PBCs) within 90 minutes. The CE-marked Specific Reveal™ antibiotic susceptibility testing (AST) System (Specific Diagnostics, Mountain View) provides phenotypic AST for 25 GN antimicrobials from PBC in an average of 5 hours without organism identification. We assessed the sensitivity and potential synergy in detecting carbapenem resistance with the BCID-GN Panel and the Reveal™ phenotypic AST in highly resistant GN organisms (GNOs). Learn more.
Real-world Performance of the ePlex® Rapid Blood Culture Identification Panels at a Tertiary Cancer Center
Session CPHMP118 – CPHM12 Molecular Diagnostic Microbiology – Potpourri
June 20, 2021, 5:30am – 2:00pm PDT | 8:30am – 5:00pm EDT
Authors
M. Cintron-Cotto, K. Raible, S. Tsui, E. Babady
Memorial Sloan Kettering Cancer Center (New York, NY)
Cancer patients, especially those receiving immunosuppressive therapy, are at a high risk of developing life-threatening infections such as bloodstream infections (BSI). Therefore, rapid identification of microorganisms present in the bloodstream is essential for optimal patient care. Traditionally, identifying microorganisms from the time the blood culture turns positive takes 24-72h. We recently implemented the ePlex® (GenMark Diagnostics) rapid blood culture identification (BCID) panels (Gram positive (BCID-GP), Gram negative (BCID-GN), and fungal (BCID-FP)). Overall, these panels can detect a total of 56 pathogens (21 Gram negative bacteria, 20 Gram positive bacteria and 15 fungi). In this study, we evaluated the real-world performance of the ePlex® BCID panels for the detection of common pathogens at our center. Learn more.
Detection of Gram Negative Resistance Markers Provided by a Syndromic Identification System
Session AARP119 – AAR02 Antibiotic Agents: Mechanisms of Action and Resistance – Emerging Mechanisms
June 20, 2021, 5:30am – 2:00pm PDT | 8:30am – 5:00pm EDT
Authors
C. Murnane, F. Zhang, A. Chandrasekaran, S. Duong, S. Juretschko
Northwell Health Laboratories (Little Neck, NY)
Identification of pathogens from positive blood cultures is of highest importance in order to provide adequate therapy for bloodstream infections. With the risk of sepsis, the fast detection of antibiotic resistance genes is similarly important. The GenMark ePlex Blood Culture Identification Gram-Negative (BCID-GN) Panel, detects 21 gram-negative bacteria and 6 resistance genes. For this study, we focused on the accuracy of detection of the resistance genes on the BCID-GN panel compared to the phenotypical results of antimicrobial susceptibility testing (AST) on Microscan. Learn more.
Detection of Gram Negative Resistance Markers Provided by a Syndromic Identification System
Session AARP119 – AAR02 Antibiotic Agents: Mechanisms of Action and Resistance – Emerging Mechanisms
June 20, 2021, 5:30am – 2:00pm PDT | 8:30am – 5:00pm EDT
Authors
C. Murnane, F. Zhang, A. Chandrasekaran, S. Duong, S. Juretschko
Northwell Health Laboratories (Little Neck, NY)
Identification of pathogens from positive blood cultures is of highest importance in order to provide adequate therapy for bloodstream infections. With the risk of sepsis, the fast detection of antibiotic resistance genes is similarly important. The GenMark ePlex Blood Culture Identification Gram-Negative (BCID-GN) Panel, detects 21 gram-negative bacteria and 6 resistance genes. For this study, we focused on the accuracy of detection of the resistance genes on the BCID-GN panel compared to the phenotypical results of antimicrobial susceptibility testing (AST) on Microscan. Learn more.
Evaluation of Four Commercial Platforms for Blood Culture Identification and Antimicrobial Resistance Detection
Session CPHM123 – Hot off the Bench: Research from CPEP Microbiology Fellows
June 22, 2021 – 3:15pm – 5:30pm PDT | 6:15pm – 8:30pm – Channel 3
Authors
R. Yee, I. I. Flores, A. Harutyunyan, P. Y. Chen, M. Precit, J. Dien Bard
Children’s Hospital Los Angeles (Los Angeles, CA)
The BioFire FilmArray Blood Culture Identification 2 Panel (BFFA), GenMark ePlex® Blood Culture Identification Panels (GM), Luminex Verigene Blood Culture Panel (LUM), and the Accelerate Pheno system (PHENO) can identify pathogens and detect antibiotic resistance directly from positive blood cultures (BCs). Here, we compare their performance at a single-center pediatric hospital. Learn more.
Respiratory Pathogen Panels
Clinical Performance of the GenMark Dx ePlex Respiratory Pathogen Panels for Upper and Lower Respiratory Tract Infections
Session CPHMP116 – CPHM12 – Molecular Diagnostic Microbiology – SARS-CoV-2
June 20, 2021, 5:30am – 2:00pm PDT | 8:30am – 5:00pm EDT
Authors
J. Jarrett, K. Uhteg, M. Forman, A. Hanlon, C. Vargas, K. Carroll, A. Valsamakis, H. Mostafa
The Johns Hopkins Hospital Medical Microbiology Laboratory (Baltimore, MD), The Johns Hopkins University School of Medicine (Baltimore, MD) and Roche Molecular Diagnostics (Pleasanton, CA)
The GenMark Dx ePlex Respiratory Pathogen Panel (RP) is a multiplexed nucleic acid test for the qualitative detection of common viral and a few bacterial causes of respiratory tract infections. The ePlex RP has received FDA clearance for nasopharyngeal swab (NPS) specimens collected in viral transport media. In this study, we evaluated the performance of the ePlex RP panel in comparison to the NxTAG Respiratory Pathogen Panel (NxTAG-RPP) from Luminex in use in our laboratory, not only for NPS but also for bronchoalveolar lavage specimens (BAL). We also evaluated the impact of implementing the ePlex RP on the test turn-around time (TAT). The newest panel from GenMark Dx, the ePlex Respiratory Pathogen Panel 2 (RP2), which added the SARS-CoV-2 target to the RP was also evaluated for NPS. Verification of the performance of the ePlex RP for both NPS and BAL showed 93.3 % and 84.9 % total agreement with the NxTAG-RPP respectively. An overall comparison of the TAT after implementing the ePlex RP as compared to the NxTAG-RPP assay showed an average decrease of almost seven-fold. Learn more.
